Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile
- 22 April 2014
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 56 (1) , 65-71
Abstract
Anthracycline-containing regimens (ACRs) are recommended for patients with diffuse large B-cell lymphoma (DLBCL). However, over 40% of elderly patients do not receive ACRs, possibly due to expected toxicities. We characterized treatment choices and compared the 3-year overall survival (OS) rates of 8262 Medicare beneficiaries diagnosed with DLBCL in 2000–2006 identified from the Surveillance, Epidemiology, and End Results (SEER)–Medicare linked database. Of the cohort, 45% had ACR with rituximab (ACR-R), 13% had ACR without R, 6% had non-ACR with R (non-ACR-R), 4% had R monotherapy, 3% had non-ACR and 29% had no systemic therapy. Patients not receiving ACR were older and/or had more comorbidities. The unadjusted OS was highest in ACR-R (65%), followed by ACR without R (55%) and non-ACR-R (44%). After adjusting patient covariates, ACR-R showed the best survival (63%). However, OS was comparable between non-ACR-R (52%) and ACR without R (52%). Non-ACR-R could be considered for patients who are poor candidates for ACR.Keywords
This publication has 34 references indexed in Scilit:
- Cancer treatment and survivorship statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for CancerJournal of Clinical Oncology, 2012
- Modulated Chemotherapy According to Modified Comprehensive Geriatric Assessment in 100 Consecutive Elderly Patients with Diffuse Large B-Cell LymphomaThe Oncologist, 2012
- Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclinesLeukemia & Lymphoma, 2011
- Diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma in the frail elderly: A phase II EORTC trial with a progressive and cautious treatment emphasizing geriatric assessmentJournal of Geriatric Oncology, 2011
- Inotuzumab ozogamicin as novel therapy in lymphomasExpert Opinion on Biological Therapy, 2010
- Oncological causes of frailty in older cancer patientsEuropean Journal of Cancer, 2007
- The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab eraLeukemia & Lymphoma, 2007
- Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2006
- Reduced-Dose CHOP Therapy for Elderly Patients with Non-Hodgkin's LymphomaLeukemia & Lymphoma, 2001